Eva Arkin, MD
Gynecology · Atlanta, GANPI 1558356147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,110 and has fallen 65.8% since, to $379 in 2025.
Across 293 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$984
- Astellas Pharma US Inc$665
- Therapeuticsmd, Inc.$568
- Pfizer$426
- Astellas Pharma Global Development$384
- Mayne Pharma Commercial LLC$254
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,17497%
- Education$1533%
- Gifts$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $984 |
| Astellas Pharma US Inc | 34 | $665 |
| Therapeuticsmd, Inc. | 61 | $568 |
| Pfizer | 25 | $426 |
| Astellas Pharma Global Development | 4 | $384 |
| Mayne Pharma Commercial LLC | 12 | $254 |
| Novo Nordisk | 14 | $203 |
| Bayer | 14 | $195 |
| Aspira Women's Health Inc | 1 | $192 |
| Myovant Sciences Inc. | 9 | $173 |
| Bausch Health US, LLC | 9 | $165 |
| Gynesonics, Inc. | 1 | $160 |
| Avion Pharmaceuticals | 10 | $148 |
| Amgen | 5 | $74 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Duchesnay USA Incorporated | 3 | $67 |
| Exeltis, USA Inc. | 4 | $57 |
| Millicent US Inc | 3 | $55 |
| Evofem Biosciences, Inc. | 4 | $54 |
| AMAG Pharmaceuticals, Inc. | 4 | $53 |
| Hologic Sales And Service, LLC | 3 | $49 |
| Nalpropion Pharmaceuticals LLC | 3 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Agile Therapeutics, Inc. | 2 | $34 |
| Lupin Inc. | 2 | $33 |
| Medtronic | 1 | $32 |
| Ascend Therapeutics US, LLC | 2 | $30 |
| Merck | 2 | $28 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Covidien LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,340 in reported general payments places this provider in the 85th percentile of 119 gynecology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 162 | $71,637 |
| Estradiol | 667 | $66,732 |
| YuvafemEstradiol | 129 | $22,461 |
| EstringEstradiol | 42 | $22,074 |
| Estradiol (Twice Weekly)Estradiol | 155 | $18,052 |
| ImvexxyEstradiol | 30 | $13,587 |
| PremproEstrogen,con/M-Progest Acet | 14 | $9,657 |
| VagifemEstradiol | 15 | $7,796 |
| ProgesteroneProgesterone, Micronized | 223 | $7,337 |
| EstraceEstradiol | 11 | $5,799 |
| ValacyclovirValacyclovir Hcl | 106 | $4,925 |
| Vivelle-DotEstradiol | 12 | $4,345 |
| DottiEstradiol | 34 | $4,197 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 26 | $2,863 |
| Clobetasol Propionate | 40 | $2,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Estring, Prempro | $426 | $103,367218 claims |
| Therapeuticsmd, Inc.Imvexxy | $568 | $13,58730 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $19 | $19719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 119 gynecology providers in Georgia.
Other gynecology in Atlanta
- Rama RaoAtlanta$343K
- Michael RandellAtlanta$196K
- Ceana NezhatAtlanta$157K
- Sujatha ReddyAtlanta$116K
- Whitney BarnesAtlanta$6K
- Michael PerryAtlanta$4K
- Nadine BeckerAtlanta$4K
- Haritha SishtlaAtlanta$2K
- Assia StepanianAtlanta$2K
- Lisa FlowersAtlanta$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.